652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

医学 克拉斯 内科学 肿瘤科 不利影响 腺癌 恶心 皮疹 癌症研究 胃肠病学 癌症 结直肠癌
作者
Kathryn C. Arbour,Salman R. Punekar,Ignacio Garrido‐Laguna,David S. Hong,Brian M. Wolpin,Meredith S. Pelster,M. Barve,Alexander Starodub,D. Sommerhalder,Sam S. Chang,Y. Zhang,Zeena Salman,X. Wang,Corinne E. Gustafson,Alexander I. Spira
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S458-S458 被引量:26
标识
DOI:10.1016/j.annonc.2023.09.1838
摘要

RMC-6236 is a novel, oral RASMULTI(ON) inhibitor that is selective for the active, GTP-bound state of both mutant and wild-type variants of the canonical RAS isoforms. Preclinical studies have demonstrated deep and sustained regressions across multiple RASMUT tumor types, particularly PDAC and NSCLC harboring KRAS glycine-12 substitutions (KRASG12X). Patients with previously treated, advanced KRASG12X mutant solid tumors were enrolled at escalating doses (10mg to 160mg once daily (QD)) of single agent RMC-6236. Additional patients with PDAC or NSCLC were enrolled at dose levels that cleared dose-limiting toxicity evaluation. As of April 24, 2023, 22 patients with KRASG12X PDAC (13 G12D, 7 G12V, 2 G12R) and 11 with KRASG12X NSCLC (5 G12D, 4 G12V, 2 G12A) were enrolled, and 14 patients with PDAC and 9 patients with NSCLC continue treatment with RMC-6236. Median prior therapies was 3 (range, 1-7). Treatment-related adverse events (TRAEs) occurring in ≥10% of patients were rash (52%), diarrhea (21%), nausea (21%), and vomiting (15%). The only Grade ≥3 TRAE was in a patient with PDAC who had a Grade 4 large intestine perforation at the site of an invasive tumor that reduced in size on treatment. Preclinical modeling predicts tumor regressions at 80mg QD or higher in humans. Preliminary clinical activity in PDAC and NSCLC was assessed at 80mg and 120mg QD. Among 14 patients (10 PDAC, 4 NSCLC) dosed at least 8 weeks prior to the data cut-off date, the objective response rate was 36% (2 confirmed and 3 unconfirmed; 2/10 PDAC and 3/4 NSCLC). Median time to onset of initial response was 6 weeks (range, 5-11). Disease control rate was 86% (12/14; 8/10 PDAC and 4/4 NSCLC). Tumor reduction was observed in 4 patients with stable disease (range, -2% to -21% by RECIST v1.1). Of the 12 patients with partial response or stable disease, 11 continue on treatment. RMC-6236 exhibits promising anti-tumor activity in patients with KRASG12X PDAC and NSCLC at doses that are well tolerated. Dose escalation is ongoing and data from additional patients will be available at the time of the meeting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助Hexagram采纳,获得10
1秒前
水蜜桃完成签到 ,获得积分10
2秒前
4秒前
鲤鱼懿轩给鲤鱼懿轩的求助进行了留言
5秒前
科研通AI2S应助那兰采纳,获得10
5秒前
红莲墨生发布了新的文献求助10
6秒前
大胆的幻巧完成签到,获得积分10
7秒前
10秒前
Owen应助科研通管家采纳,获得10
10秒前
天天快乐应助科研通管家采纳,获得10
10秒前
赘婿应助科研通管家采纳,获得10
10秒前
隐形曼青应助科研通管家采纳,获得10
10秒前
李健应助科研通管家采纳,获得10
10秒前
桐桐应助科研通管家采纳,获得10
10秒前
852应助科研通管家采纳,获得10
10秒前
年轻馒头应助科研通管家采纳,获得10
11秒前
Ava应助科研通管家采纳,获得10
11秒前
eric888应助科研通管家采纳,获得100
11秒前
SciGPT应助科研通管家采纳,获得10
11秒前
传奇3应助3237924531采纳,获得10
12秒前
12秒前
14秒前
Hexagram发布了新的文献求助10
16秒前
完美世界应助贪玩的甜瓜采纳,获得10
16秒前
笨笨西牛完成签到 ,获得积分0
16秒前
欣慰铁身完成签到,获得积分10
17秒前
JerryJi发布了新的文献求助10
18秒前
量子星尘发布了新的文献求助10
19秒前
蓝色的帐篷完成签到 ,获得积分10
19秒前
20秒前
hzhniubility完成签到,获得积分10
20秒前
斯文败类应助AnleHrc采纳,获得10
22秒前
大知闲闲完成签到 ,获得积分10
24秒前
正直如阳完成签到,获得积分10
25秒前
orixero应助Hexagram采纳,获得10
25秒前
好好发布了新的文献求助10
26秒前
26秒前
evans完成签到,获得积分10
27秒前
ding应助EliGolden采纳,获得10
27秒前
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975986
求助须知:如何正确求助?哪些是违规求助? 3520289
关于积分的说明 11202025
捐赠科研通 3256778
什么是DOI,文献DOI怎么找? 1798453
邀请新用户注册赠送积分活动 877605
科研通“疑难数据库(出版商)”最低求助积分说明 806482